Related news from
Wed, 03 Apr 2024 15:30:04 +0000	Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue? Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Fri, 22 Mar 2024 18:00:00 +0000	Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.
Wed, 06 Mar 2024 17:33:00 +0000	Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.
Tue, 05 Mar 2024 15:07:00 +0000	Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.
Tue, 05 Mar 2024 14:13:38 +0000	Nektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call Transcript Nektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call Transcript March 4, 2024 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.22 EPS, expectations were $-0.2. NKTR isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you for […]
Tue, 05 Mar 2024 14:00:00 +0000	Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced the initiation of its Phase 2b clinical trial evaluating rezpegaldesleukin in patients with severe to very severe alopecia areata.
Tue, 05 Mar 2024 12:19:25 +0000	Q4 2023 Nektar Therapeutics Earnings Call Q4 2023 Nektar Therapeutics Earnings Call
Mon, 04 Mar 2024 22:30:02 +0000	Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates Nektar (NKTR) delivered earnings and revenue surprises of -10% and 39.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Mon, 04 Mar 2024 21:51:56 +0000	Nektar Therapeutics (NKTR) Reports Fiscal Year-End and Q4 2023 Results Financial Highlights Reflect Cost Management Amidst R&D Progress
Mon, 04 Mar 2024 21:15:00 +0000	Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2023.
Mon, 04 Mar 2024 13:30:00 +0000	Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced that it has entered into a securities purchase agreement with TCGX, an institutional accredited investor, to sell securities in a private placement financing (the "PIPE") for gross proceeds of $30 million, before deducting expenses.
Tue, 27 Feb 2024 23:00:00 +0000	Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44th Annual Health Care Conference in Boston on Tuesday, March 5, 2024 at 2:10 p.m. Eastern Time.
Mon, 26 Feb 2024 23:00:00 +0000	Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2023 on Monday, March 4, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
Tue, 20 Feb 2024 15:00:57 +0000	Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fri, 16 Feb 2024 13:45:36 +0000	Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans? We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Tue, 09 Jan 2024 14:25:00 +0000	BioCryst (BCRX) Moves 25.6% Higher: Will This Strength Last? BioCryst (BCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Wed, 03 Jan 2024 23:00:00 +0000	Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA Nektar (Nasdaq: NKTR) management is scheduled to present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 5:15 p.m. Pacific Time. The presentation and Q&A session will be accessible via a Webcast through a link posted on the Investor Events Calendar section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. This webcast will be available for replay until February 9, 2024.
Sat, 30 Dec 2023 12:38:12 +0000	Following a 75% decline over last year, recent gains may please Nektar Therapeutics (NASDAQ:NKTR) institutional owners Key Insights Given the large stake in the stock by institutions, Nektar Therapeutics' stock price might be vulnerable...
Mon, 11 Dec 2023 23:00:00 +0000	Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting Nektar Therapeutics (NASDAQ:NKTR) announced that collaborators from the Cairo Laboratory at New York Medical College presented a poster highlighting new preclinical data on NKTR-255 at the 65th American Society of Hematology (ASH) Annual Meeting demonstrating that NKTR-255 significantly enhanced the cytotoxicity of expanded Natural Killer (NK) cells when combined with obinutuzumab against rituximab-resistant BL cells and significantly improved the survival of mice xenografted with Raji-4RH compa
Fri, 08 Dec 2023 16:30:40 +0000	Why Is Jazz (JAZZ) Up 2.6% Since Last Earnings Report? Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.